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OBJECTIVES This study was designed to investigate the potential of circumferential pulmonary vein (PV)
ablation for atrial fibrillation (AF) to maintain sinus rhythm (SR) over time, thus reducing
mortality and morbidity while enhancing quality of life (QoL).
BACKGROUND Circumferential PV ablation is safe and effective, but the long-term outcomes and its impact
on QoL have not been assessed or compared with those for medical therapy.
METHODS We examined the clinical course of 1,171 consecutive patients with symptomatic AF who
were referred to us between January 1998 and March 2001. The 589 ablated patients were
compared with the 582 who received antiarrhythmic medications for SR control. The
QoL of 109 ablated and 102 medically treated patients was measured with the SF-36
survey.
RESULTS Median follow-up was 900 days (range 161 to 1,508 days). Kaplan-Meier analysis showed
observed survival for ablated patients was longer than among patients treated medically
(p  0.001), and not different from that expected for healthy persons of the same gender
and calendar year of birth (p  0.55). Cox proportional-hazards model revealed in the
ablation group hazard ratios of 0.46 (95% confidence interval [CI], 0.31 to 0.68; p 
0.001) for all-cause mortality, of 0.45 (95% CI, 0.31 to 0.64; p  0.001) for morbidities
mainly due to heart failure and ischemic cerebrovascular events, and of 0.30 (95% CI,
0.24 to 0.37; p  0.001) for AF recurrence. Ablated patients’ QoL, different from
patients treated medically, reached normative levels at six months and remained
unchanged at one year.
CONCLUSIONS Pulmonary vein ablation improves mortality, morbidity, and QoL as compared with medical
therapy. Our findings pave the way for randomized trials to prospect a wider application of
ablation therapy for AF. (J Am Coll Cardiol 2003;42:185–97) © 2003 by the American
College of Cardiology Foundation
Atrial fibrillation (AF), the most common of all therapy-
demanding cardiac arrhythmias, afflicts about 5% of a
general middle-age population and is associated with high
risk of stroke and death (1–3). Patients may experience a
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severely diminished quality of life (QoL) and frequent
hospitalization (3,4).
The desirable therapeutic goal in treating AF is to restore
and maintain sinus rhythm (SR)—thus avoiding long-term
anticoagulation—reducing thromboembolic risk, enhancing
cardiac performance, and improving survival (5,6).
However, arrhythmia recurs within one to two years in at
least 50% of patients despite antiarrhythmic drug therapy,
which in turn may increase mortality (5–8). This has
catalyzed the development of nonpharmacologic approaches
to fully restore SR control over the atrium (9,10). The
established dominance of the left atrium (LA) in the region
of pulmonary veins (PVs) in triggering and/or maintaining
AF prompted the development of new strategies for radio-
frequency (RF) transcatheter ablation at this critical region
(11–14). We devised circumferential PV ablation, a safe and
effective therapeutic strategy for AF, which targets the
venous-atrial junction (12,13). Its outcomes, however, had
not been properly assessed or compared with those for
medical therapy in a controlled, long-term study.
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We report on the clinical course of 1,171 patients with
AF. The outcomes of the 589 patients who underwent
circumferential PV ablation were compared with those of
the 582 subjects who received medical treatment for SR
control. The purpose of the study was to investigate the
potential of ablation to maintain SR over time, thus reduc-
ing mortality and morbidity while enhancing QoL.
METHODS
Study population. Between January 1998 and March
2001, a total of 1,171 consecutive patients from all over Italy
with symptomatic AF were referred to San Raffaele Uni-
versity Hospital’s cardiac electrophysiology unit. We ex-
cluded patients because of the following reasons: contrain-
dication to anticoagulation; New York Heart Association
functional class IV; myocardial infarction or cardiac surgery
within the past three months; sick sinus syndrome or
atrioventricular conduction disturbances without an artifi-
cial pacemaker; ventricular tachyarrhythmias; thyroid dys-
function; or unsuccessful cardioversion to SR by drugs
and/or electroshock.
The decision to undergo catheter ablation or medical
treatment was left to the patient’s own preferences or to the
judgment of the electrophysiologist involved in each case,
who decided intervention in cases of 2 previous ineffective
trials with antiarrhythmic drugs, 2 AF-related hospital
admissions during the 2 years before entering the study, or
2 years of antiarrhythmic drug treatment.
The study was approved by the hospital’s ethics commit-
tee, and all patients gave their written informed consent.
Treatment of AF. ABLATED PATIENTS. Circumferential
PV ablation was performed in 589 patients. All patients had
to be taking effective oral anticoagulation medication for at
least four weeks. Oral anticoagulants were replaced on
admission by heparin to maintain a partial thromboplastin
time of 60 to 90 s (control 30 s). Heparin was stopped 4 to
6 h before ablation, as trans-septal catheterization was
required. The ablation technique’s details have been pub-
lished previously (12,13). Briefly, three-dimensional LA
maps and PV profiles were reconstructed through a trans-
septal route using a nonfluoroscopic electrogeometric map-
ping system (CARTO, Biosense-Webster, Diamond Bar,
California) (10,12,13). After characterizing PV ostia, RF
energy was delivered by the distal electrode of the navigation
catheter to create circular lines of conduction block around
each vein ostium. An intravenous dose of 75 U heparin/kg
of body weight was administered during ablation, followed
by an infusion to maintain a partial thromboplastin time of
60 to 90 s.
This purely anatomic approach yields either an atrio-
venous electrical disconnection, as demonstrated by elimi-
nation of PV ostial potentials and absence of discrete
electrical activity inside the lesion during pacing outside the
ablation line, or a profound atrial electroanatomic remod-
eling, as expressed by voltage abatement inside and around
the encircled areas, partially involving the LA posterior wall
(Fig. 1) (12,13).
Procedures averaged 165 22 min, with an ablation time
of 59  15 min for delivering 93  18 RF pulses. Four
patients (0.7%) required pericardiocentesis for cardiac tam-
ponade. There were no strokes or other thromboembolic
events. After ablation and during follow-up, no patient devel-
oped symptoms suggestive of PV stenosis. Transesophageal
Doppler-echocardiography, performed within three days and
one to six months after ablation, showed no high-velocity
turbulence near the ostia suggestive of PV narrowing in any of
the patients. Post-RF, all patients were given warfarin, whereas
a previously ineffective antiarrhythmic was prescribed to pa-
tients (n  115) who had in-hospital AF episodes and/or
needed electrical cardioversion at the end of the procedure. At
discharge, all patients were in SR. Both antiarrhythmics and
anticoagulation were discontinued at three months in the
absence of recurrences, with evidence of LA transport function
by Doppler-echocardiography.
MEDICALLY TREATED PATIENTS. This study group com-
prised 582 subjects who were given antiarrhythmic medica-
tions for SR control throughout the follow-up period. In
patients with intermittent AF, antiarrhythmic therapy was
initiated during SR, whereas patients with nonself-
terminating or chronic AF underwent pharmacological and,
if necessary, electrical cardioversion followed by prophylac-
tic antiarrhythmic agents to maintain SR. Anticoagulation
was used in accordance with published guidelines (1,6) and
could be stopped at the physician’s discretion if SR had been
maintained for at least three months.
At hospital discharge, all patients were in SR, 33% were
on amiodarone, 17% on propafenone, 15% on flecainide,
13% on sotalol, 9% on quinidine, 6% on disopyramide, and
7% on 1 antiarrhythmic agent.
Follow-up and outcome measures. At referral, all pa-
tients’ data were prospectively recorded in a computerized
database. Follow-up began when patients were discharged,
and we considered information until April 2002.
Follow-up consisted of outpatient visits with serial 12-
lead electrocardiograms (ECGs), echocardiograms, and
24-h Holter monitoring performed on symptom recurrence
or routinely at 1, 3, 6, 9, and 12 months in the first year, and
Abbreviations and Acronyms
AF  atrial fibrillation
CAD  coronary artery disease
CI  confidence interval
ECG  electrocardiogram
HR  hazard ratio
LA  left atrial/atrium
MI  myocardial infarction
PV  pulmonary vein
QoL  quality of life
RF  radiofrequency
SR  sinus rhythm
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Figure 1. Three-dimensional left atrial (LA) voltage maps (posteroanterior view: left, preablation; right, postablation), depicting peak-to-peak bipolar electrogram amplitude. Color red represents lowest
voltage, and purple, highest voltage. Claret red spheres represent radiofrequency lesions. In postablation, areas within and around the ablation lines, involving to some extent the LA posterior wall, show
low-amplitude (0.1 mV) electrograms. Preablation insets show pulmonary vein (PV) ostial potentials indicating the activation of muscular fibers capable of conducting impulses in or out of the veins. By
creation of lesions around each vein ostium, PV potentials are no longer detected (insets) at the same ostial points recorded before ablation. LSPV  left superior pulmonary vein; LIPV  left inferior
pulmonary vein; RSPV  right superior pulmonary vein; RIPV  right inferior pulmonary vein.
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every 6 months thereafter. Patients were also asked to
maintain a log of symptoms suggestive of AF, and tran-
stelephonic monitoring was considered to document the
cause of symptoms. Moreover, patients, relatives, and pri-
mary physicians were also advised to report, by phone or
E-mail, adverse events and hospitalizations occurring in-
between visits.
Atrial fibrillation recurrence was defined as a symptom-
atic episode lasting more than 10 min and confirmed by
ECG. To estimate the arrhythmia burden after the first
recurrence, we measured the frequency of relapses as
episodes/patient-year. Adverse events included heart failure
requiring IV therapy, myocardial infarction (MI), cerebro-
vascular accident, transient ischemic attack (TIA), and
peripheral embolism. Hospitalizations were measured as
times/year. We examined hospital records, death certifi-
cates, and autopsy reports, and we classified deaths as either
cardiovascular or noncardiovascular. An independent com-
mittee classified all events after masked review of the data.
In September 2000 we started measuring QoL with the
36-Item Short-Form General Health Survey (SF-36)
(4,15,16). To assess the one-year time course of QoL we
reported results of consecutive ablated (n  109) and
medically treated (n  102) patients discharged by March
2001. Patients were interviewed at the time of admission
and at three-month intervals thereafter.
Statistical analysis. Continuous data were previously ex-
amined by normality test. Parametric or nonparametric tests
for independent or related samples were used as appropriate,
and were specifically reported in the Results section. For
discrete variables, the chi-squared test was performed,
unless the Fisher exact test was required for frequency tables
when 20% of the expected values were 5. Observed
survival rates for both groups—presented as Kaplan-Meier
plots—were compared among them and with the life-
expectancy for persons of the same gender and calendar year
of birth in the general Italian population by two- and
one-sample log-rank tests (17).
A Cox proportional-hazards model was used to estimate
the effect of treatment on all-cause mortality and freedom
from adverse events or AF recurrence, while adjusting for
other prognostic factors. The effect of being in SR on
mortality and morbidity was estimated by introducing into
the Cox model a time-dependent variable that assumed a
Table 1. Baseline Characteristics of Patients Who Underwent Ablation and of Patients Treated
Medically at Time of Hospital Admission
Characteristic
Ablation Group
(n  589)
Medical Group
(n  582) p Value
Age (yrs) 65 9* 65  10 0.99
Male gender (%) 58 59 0.95¶
Follow-up duration, median (range), (days) 861 (161–1491) 911 (179–1508) 0.22#
Out-patient visits (no./yrs) 3.2  2.1 3.0  2.4 0.13
History of AF†
Duration (yrs) 5.5  2.8 3.6  1.9 0.001
Paroxysmal (% of patients) 69 71 0.45¶
Chronic (% of patients) 31 29 0.45¶
Antiarrhythmic drugs (no. of trials) 3.1  2.1 2.3  1.5 0.001
Medical history and conditions (% of patients)
No cardiovascular disease 34 35 0.72¶
Hypertension 46 43 0.29¶
Diabetes 11 10 0.60¶
Cigarette smoking 49 46 0.34¶
Cholesterol 5.17 mmol/l 42 37 0.08¶
CAD 23 22 0.81¶
Dilated cardiomyopathy 5 4 0.40¶
Valvular disease 9 8 0.39¶
Prior stroke or TIA 16 15 0.12¶
Chronic lung disease 9 10 0.55¶
Cardiovascular drugs used 42 41 0.73¶
New York Heart Association functional class 1.3  0.9 1.2  0.7 0.09
Hospital admission (times/yrs)‡ 2.4  1.5 2.2  1.6 0.04
Echocardiography
LV ejection fraction (%) 54  12 55  14 0.22
LV fractional shortening (%) 33  10 34  7 0.07
LA diameter, long-axis view (mm) 46  9 45  8 0.06
LV mass index (g/m2) 138  56 135  65 0.53
Peak mitral A-wave velocity (m/s)§ 0.57  0.08 0.56  0.10 0.11
*Plus-minus are means  SD. †Paroxysmal AF was defined as recurrent self-terminating episodes lasting fewer than seven days;
chronic AF as AF persistent for at least seven days. ‡Hospital admissions refer to the two years before entering the study. §Data
relative to patients evaluated during sinus rhythm. p values by independent-samples t test. ¶By chi-squared test. #By
independent-samples Wilcoxon-Mann-Whitney U test.
AF  atrial fibrillation; CAD  coronary artery disease; LA  left atrial; LV  left ventricular; TIA  transient ischemic
attack.
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value of 1 until the first relapse occurred, and 0 thereafter.
The AF burden was analyzed under the assumption of a
Poisson distribution for the number of observed relapses to
calculate the rate ratio, as the ratio of the observed frequen-
cies of recurrence for the two groups, and the 95% confi-
dence interval (CI). Generalized linear models for repeated
measures were used to model change in QoL scores over
time (18). Separate multivariate models, adjusted for rele-
vant baseline characteristics listed in Figure 3, were used to
assess changes in SF-36 physical and mental summary
component scores, and the independent relationship of
treatment and AF recurrence with QoL. Analyses were
performed by S-PLUS-for-Windows (release 6, Basing-
stoke, Hampshire, UK) and SPSS-for-Windows (release
11.01, SPSS Inc., Chicago, Illinois). A two-sided p  0.05
was regarded as significant.
RESULTS
Patients. The two treatment groups appeared well bal-
anced, except for longer arrhythmia duration, greater num-
ber of antiarrhythmics tried, and more frequent hospitaliza-
tion in the ablation group (Table 1). The overall median
follow-up period was 900 days, with no significant differ-
ence in duration and intensity between groups. Nineteen
patients (2%) were lost to follow-up.
Survival. At the latest assessment, 38 (6%) ablated patients
and 83 (14%) in the medical group had died (Table 2).
Cardiovascular deaths occurred less frequently in the abla-
tion group with lower number of fatalities due to heart
failure and ischemic strokes and no sudden death, although
noncardiovascular mortality was comparable between the
two groups. Of the total 77 patients who died of cardiovas-
cular reasons, 58 (75%) had concurrent AF at time of death.
Of note, 23 (74%) and 11 (61%) of the 31 and 18 deaths due
to heart failure and MI occurred in subjects with AF.
Observed survival for ablated patients was longer than
among medically treated patients and not different from that
expected for age- and gender-matched persons of the Italian
population (Fig. 2). A reduction of 54% occurred in the risk
of death for ablated patients (p  0.001), with history of
coronary artery disease (CAD), ejection fraction (EF)
45%, LV mass index 125 g/m2, and age 65 years
independently associated with higher risk of dying (Fig.
3A).
Morbidities. Forty-six (8%) ablated and 98 (19%) medi-
cally treated patients were managed for a total of 54 and 117
adverse events, respectively (Table 2). Heart failures and
ischemic cerebrovascular events occurred more frequently in
the medical group. The majority of patients (n  104, 72%)
with adverse events had AF at the time of the event. All four
cases of peripheral embolism occurred in subjects with AF,
as well as 89% and 79% of the 35 TIAs and 19 ischemic
strokes. Respectively, 54% and 49% of ablated and medically
managed patients had thromboembolic complications while
receiving inadequate (international normalized ratio 2) or
no anticoagulant therapy (p  0.75, by chi-squared test).
Ablated patients were less than half as likely as medically
treated patients to have morbid events (hazard ratio [HR],
0.45; 95% CI, 0.31 to 0.64). Risk factors of death predicted
adverse events too, as did history of cerebrovascular insults
and being male (Fig. 3B). The adverse event-free survival
probabilities were significantly higher among ablated pa-
tients (Fig. 4).
Effect of SR on mortality and morbidity. Maintenance of
SR, as a time-dependent variable, was associated with
significantly lower mortality and adverse event rates, either
considering all patients (HR, 0.24; 95% CI, 0.16 to 0.37,
and HR, 0.22; 95% CI, 0.15 to 0.31, respectively) or the two
treatment groups (ablation: HR, 0.21; 95% CI, 0.09 to 0.48,
and HR, 0.33; 95% CI, 0.16 to 0.68; medical: HR, 0.19;
95% CI, 0.12 to 0.32, and HR, 0.13; 95% CI, 0.08 to 0.21).
We also found a somewhat reduced beneficial prognostic
value of ablation, with no substantial changes in other
predictive factors of death and adverse events (Figs. 3A and
3B).
Recurrences, LA size and function, and hospitalization.
At final analysis, 120 ablated and 340 medically treated
patients had their first relapses. Of the 120 recurrent ablated
patients, 31 (26%) developed recurrent persistent AF, as
Table 2. Causes of Death and Adverse Events During
Follow-Up
Ablation Group
(n  589)
Medical Group
(n  582)
TotalNo. of Patients
Death
Cardiovascular causes 18 59 77
Congestive heart failure 8 23 31
Myocardial infarction 8 10 18
Sudden* 0 12 12
Ischemic stroke† 2 14 16
Noncardiovascular causes 20 24 44
Respiratory failure 5 7 12
Cancer 8 9 17
Infection 3 2 5
Other 4 6 10
Total 38 83 121
No. of Events Total
Adverse event‡
Congestive heart failure 32 57 89
Myocardial infarction 7 8 15
Peripheral embolism 1 3 4
TIA 8 27 35
Ischemic stroke 4 15 19
Hemorrhagic stroke 2 7 9
Total 54 117 171
No. of patients with events 46 98 144
*At the time of death, 6 patients were on amiodarone, 3 on flecainide, 1 on sotalol,
and 2 on propafenone and sotalol. †At the time of death all but 7 patients (1 ablated
and 6 medically treated, p  0.70 by the Fisher exact test) were on warfarin with a
mean international normalized ratio (INR) of 2.3  1.0 (range, 1.8–3.6). ‡Among
the 4 peripheral embolisms, 35 transient ischemic attacks (TIAs) 19 ischemic, and 9
hemorrhagic strokes, 2, 26, 14, and 8 occurred during warfarin therapy, with mean
INRs before the event of 2.4  0.3 (range, 2.2–2.6), 2.1  0.9 (range, 1.7–3.6), 2.0
 1.2 (range, 1.8–3.2), and 2.5  0.5 (range, 1.9–4.2), respectively.
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Figure 2. Observed and expected survival in the ablation and medical groups. The observed survival among ablation patients did not differ (p  0.55) from
the expected (A) and was significantly longer than that observed in the medical group, whose survival proved worse than that expected (B). Observed survival
probabilities were 98%, 95%, and 92% at one, two, and three years, respectively, among ablated patients, and 96%, 90%, and 86%, respectively, among those
medically treated (p  0.001).
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Figure 3. The hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of death, adverse events, and atrial fibrillation (AF) recurrence in the ablation group as compared with the medical group.
In A and B, for each covariate, the corresponding HR and 95% CI are represented before (blue line) and after (red line) the introduction into the Cox model of maintenance of sinus rhythm (SR) as
time-dependent variables. There was evidence of nonproportional hazards between the two treatment groups over time (p  0.001) for recurrent AF, with a significant treatment interaction (p  0.001); the
corresponding HR for ablation was 0.30 (95% CI, 0.24 to 0.37) and must be interpreted as an average value during the entire follow-up period (C), as well as the other HRs indicated by asterisks (*) in A
and B. By entering maintenance of SR, ablation patients’ HRs for the risk of all-cause death and adverse events went from 0.46 (95% CI, 0.31 to 0.68; p  0.001) and 0.45 (95% CI, 0.31 to 0.64; p  0.001)
to 0.66 (95% CI, 0.44 to 0.97; p  0.04) and 0.61 (95% CI, 0.42 to 0.86; p  0.007), respectively. CAD  coronary artery disease; EF  ejection fraction; LA  left atrial; LV  left ventricular; TIA 
transient ischemic attack.
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well as 221 (65%) of the 340 medically managed patients
with recurrences. Among the 45 recurrent ablated patients
who had history of chronic AF, 28 (62%) developed
paroxysmal AF. Of note, 12 (2%) ablated patients developed
atypical LA flutters, which were successfully treated with
linear lesions from the left inferior PV to the mitral annulus
(60%) or connecting the superior (25%) or the inferior
(15%) PVs.
Recurrence rates were significantly lower among ablated
patients (Fig. 5). The protective effect of ablation increased
over time, highlighting that patients had their arrhythmia
cured if they did not lapse back to AF within 10 months.
Multivariate regression analysis was performed, including all
variables listed in Figure 3, as well as early (within the first
two weeks) recurrence of AF, need of cardioversion after
completing ablation, and low-voltage encircled PV ostial
area 15% of LA surface: only LA diameter 45 mm and
reduced encircled area independently predicted long-term
recurrences in ablated patients (HR, 3.37; 95% CI, 2.19 to
5.19, and HR, 3.58; 95% CI, 2.41 to 5.32, respectively);
arrhythmia type and duration did not.
Arrhythmia burdens of 5.4 and 2.1 relapses/patient-year
were observed among medically treated and ablated pa-
tients, respectively (rate ratio, 0.38; 95% CI, 0.32 to 0.56).
A nearly fourfold mean reduction in LA size and 1.5-fold
mean increase in peak A-wave velocity were observed in
nonrecurrent ablated patients compared with not-recurrent
patients in the medical group (Table 3).
Hospitalizations were reduced in ablated patients with or
without recurrences (Table 4). Not-recurrent medically
treated patients were also hospitalized less, although more
than not-recurrent ablated patients, with admissions mostly
(53%) due to drug-related side effects.
Quality of life. As Figure 6 shows, at baseline both
treatment groups, which were clinically comparable (Table
5), rated their health status similarly and lower than persons
of the same sex and gender in the general Italian population
(p  0.001, by unpaired t test with Bonferroni correction)
(16). Both physical and mental functioning scores showed
similar changes over time in each group. A significant (p 
0.007) time trend over one year was detected only in ablated
patients (p  0.004), who reached normative levels at six
months, with no further changes at one year. On multivar-
iate analysis, AF recurrence was independently associated
with significant reductions in physical and mental function-
ing in the medical group and impaired psychological well-
being among ablated patients (all p  0.01).
DISCUSSION
We found circumferential PV ablation for AF improves
mortality, morbidity, and QoL, as compared to medical
Figure 4. Kaplan-Meier estimates of the percentages of patients remaining free of any adverse events. Percentages of patients event-free were 97%, 94%,
and 91% at one, two, and three years, respectively, among ablated patients, and 93%, 87%, and 81%, respectively, among those medically treated (p 0.001).
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Figure 5. Kaplan-Meier estimates of the percentages of patients remaining free of atrial fibrillation (AF) recurrence. Percentages of AF-free patients were 84%, 79%, and 78%, respectively, at one, two, and
three years among ablated patients, and 61%, 47%, and 37%, respectively, among those medically treated (p  0.001). The favorable effect of ablation on AF recurrence increased over time during the entire
follow-up period, with an average risk of 0.30 (inset). 193
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therapy. Atrial fibrillation has been associated with a dou-
bling of the risk for death and a quintupling of that for
stroke compared with subjects in SR, after adjustment for
coexisting cardiovascular conditions (2,3). Our ablated pa-
tients had a remarkable HR for death of 0.46 and reductions
of 70% and 55% in the risk of recurrent AF and major
morbidities, respectively, due mainly to heart failure and
ischemic cerebrovascular insults. It is significant that abla-
tion lengthened survival to almost that expected for the
general population, emphasizing the importance of poten-
tially preventable deaths among AF patients. However, the
extent of this benefit must be interpreted in light of the fact
that a sizable proportion of our patients had no cardiovas-
cular disease and the median follow-up period was 900 days.
Accordingly, data on longer follow-up will be needed.
Maintenance of SR and clinical implications. Another
important finding was that maintenance of SR as a time-
dependent variable was associated with reductions in the
risk of death (76%) and adverse events (78%), with ablation
still preserving its beneficial effects, yet with relatively higher
HRs of dying (0.66 vs. 0.46) or experiencing morbid events
(0.61 vs. 0.45). That ablation still preserved its favorable
prognostic effects would suggest the potential advantage of
maintaining SR with antifibrillatory agents is outweighed by
their proclivity to cause life-threatening proarrhythmia and
serious side effects or to exacerbate ischemia or heart failure
by their negative inotropic actions (5–8). Indeed, sudden
death and heart failure were key contributors in shortening
survival in the medical group as were ischemic cerebrovas-
cular events in increasing morbidity. In the latter, the higher
incidence of TIAs and strokes was likely secondary to
recurrent AF, as no significant difference was noted in the
proportions of patients not receiving anticoagulants or with
inadequate anticoagulation between the two treatment
groups, whereas concurrent AF was observed in the vast
majority of cases with thromboembolic events.
With regard to this, it is noteworthy to emphasize that in
our patient population of ablated and nonablated patients,
whose characteristics were remarkable for the absence of
structural heart disease other than hypertension, many
patients who developed or died from congestive heart failure
or MI had recurrent AF. Taken together, all these findings
imply maintenance of SR affects prognosis, perhaps because
of improved hemodynamics and atrial transport function,
with greater benefit for patients with stiff ventricles, such as
those with hypertension; other benefits include reduced
risks of tachycardia-mediated cardiomyopathy and of cere-
bral and coronary artery thromboembolism (5,6). That SR
resulted as a strong prognostic determinant, with coexisting
heart conditions such as CAD, LV hypertrophy, and
systolic dysfunction all preserving their predictive power,
reinforces the concept that, AF, by itself or as hastening
factor, may cause excess mortality and morbidity. Its pre-
vention and treatment should, therefore, always be pursued.
Ablation was three-fold as effective as were drugs in
preventing recurrences of AF, despite the fact that the
ablation group had more patients with longer arrhythmia
duration and more previously failed drug trials, and the
recurrence rates among our medically treated patients were
very similar to those of previous studies using various
antifibrillatory compounds, including the relatively safe
amiodarone (5–7). Moreover, the arrhythmia burden among
ablated patients was approximately three-fold as low as that
in the medical-therapy group. Of note, both recurrent and
nonrecurrent ablated patients experienced significantly
fewer hospitalizations that patients treated medically, and
this has implications for overall cost.
Paroxysmal versus chronic AF. Circumferential PV abla-
tion was efficacious in both paroxysmal and chronic AF.
This indicates our anatomic approach produces either the
electrical isolation of PV foci triggering the arrhythmia or a
profound electroanatomic remodeling involving the atrial
tissue adjacent to vein ostia-substrate for AF maintenance
(12,13). Indeed, a reduced extent of the encircled PV ostial
area was a strong predictor of recurrences. This may explain
why the success rates of this ablative technique in both
arrhythmia types are higher than in mapping-guided strat-
egies isolating PVs at their ostia, without excluding any
atrial myocardium (14). Moreover, circumferential PV ab-
Table 3. Impact of Treatment on LA Size and Transport Function in Patients Grouped According to the Occurrence of Recurrent
Atrial Fibrillation
LA Size* LA Transport Function*
Recurrent Nonrecurrent Recurrent† Nonrecurrent
Ablation 4.6 (10.0 to 0.8) 11.51 (15.41 to 7.61)‡ 0.05 (0.02 to 0.11) 0.12 (0.08 to 0.17)§
Medical therapy 2.13 (5.33 to 1.07) 2.92 (5.37 to 0.47)‡ 0.12 (0.24 to 0.21) 0.08 (0.01 to 0.16)§
*Echocardiographic left atrial (LA) size was defined as medial-lateral atrial diameter in mm and LA transport function as peak mitral A-wave velocity in m/s; their changes are
presented as mean values with corresponding 95% confidence intervals in parentheses, or medians with 25th to 75th percentiles in parentheses, as appropriate. †Data relative to
patients evaluated during sinus rhythm. ‡p values 0.01 by related-samples t test. §p values 0.01 by related-samples Wilcoxon signed-rank test, for changes from baseline to
the latest follow-up echocardiographic examination.
Table 4. Impact of Treatment on Hospitalization in Patients
Grouped According to the Occurrence of Recurrent Atrial
Fibrillation*
Recurrent
p
Value† Nonrecurrent
p
Value†
Ablation 0.7 (1.9 to 0.2) 0.04 1.8 (4.7 to 0.7) 0.001
Medical
therapy
0.5 (0.7 to 2.8) 0.43 1.2 (2.9 to 0.8) 0.01
*Changes in hospitalization rates (times/year), from two years before entering the
study and during follow-up, are described by medians with 25th to 75th percentiles
in parentheses. †p values are by related-samples Wilcoxon signed-rank test.
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Figure 6. Changes in quality of life over time in the ablation and medical groups. The computation of aggregate scores for the physical (PCS, A) and mental
(MCS, B) components and missing data were handled as suggested by the developers of the SF-36 (15).
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lation appears to significantly alter the atrial anatomy
necessary for AF initiation and/or maintenance as demon-
strated by the marked LA size reduction with improved
transport function in patients with no recurrence.
Health status. To evaluate new therapy thoroughly, its
impact on the quality of patients’ everyday lives should also
be defined. Our ablated patients, differently from patients
treated medically, enjoyed better general health, and their
physical and psychological well-being scores reached the
levels of the general population, suggesting an all-around
impact. The possibility of a persistent placebo effect of
ablation appears minimal, because QoL at one-year was
essentially the same as that at six months; moreover, AF
recurrence also negatively impacted health status in ablated
patients.
Study limitations. Our findings and conclusions should be
interpreted in the light of the limitations imposed by a
nonrandomized assignment of patients to the two treatment
groups. With such an observational design, selection bias
cannot be excluded; however, the inclusion of consecutive
patients, the analysis of all data based on multivariate
regression models, and the review of all events by an
independent committee unaware of the two treatment
groups minimized such bias. Moreover, although the con-
sidered clinical characteristics of the two groups were not
identical, the differences did not substantially indicate a
more favorable prognosis for one group over the other.
Recurrences were quantified based on patient symptoms
and serial ECGs and Holter monitors, whereas transtele-
phonic monitors were available for symptomatic patients.
Therefore, our criterion to define AF recurrence may have
underestimated the true recurrence rates, as many AF
episodes may be asymptomatic. Our findings deserve careful
consideration, because they were obtained in a very experi-
enced center and need to be confirmed in further studies.
Conclusions. Because in both our ablation and antiar-
rhythmic groups, SR maintenance was associated with
significantly lower mortality and adverse event rates, the
present study questions the results of three recent AF trials
(Pharmacological Intervention in Atrial Fibrillation, Atrial
Fibrillation Follow-up Investigation of Rhythm Manage-
ment, and Rate Control vs. Electrical Cardioversion for
Persistent Atrial Fibrillation [PIAF, AFFIRM, and RACE,
respectively]), which demonstrated, contrary to prevailing
practice, the lack of benefit of rhythm control over heart rate
control by drugs (19–21).
On the one hand, these conflicting results could be
explained by the fact that it is difficult to directly compare
our study with others because patient populations are
inevitably different. Indeed, RACE and AFFIRM enrolled
only older patients with one or more risk factors for stroke,
most of whom had persistent AF (20,21). Younger patients
with structurally normal hearts and paroxysmal arrhythmia
were disproportionately represented in these trials, and
results could not be generalized to a broader AF population;
thus, curing AF and maintaining SR may still be the goal,
at least in some groups of patients.
On the other hand, it should be noted that it is intrinsi-
cally unlikely that SR is per se harmful to the patient’s life,
and one could argue that the warning trend toward a higher
risk of death in the rhythm-control groups in both RACE
and AFFIRM studies could be attributable to the means
used to achieve SR or to the means used for its long-term
maintenance (20,21). Thus, we believe that the quest for
safer and more effective catheter ablation techniques for
curing AF will, and should, continue. In the meantime,
although this cohort follow-up study suggests that PV
ablation could be attempted not only in patients with severe
drug-refractory AF, the purpose it really serves is to provide
Table 5. Baseline Clinical Characteristics at Time of Hospital Admission of Ablated and
Medically Treated Patients Included in the Quality of Life Analysis
Characteristic
Ablation Group
(n  109)
Medical Group
(n  102) p Value
Age (yrs) 66  8* 64  11 0.13†
Male gender (%) 56 57 0.88‡
History of AF
Duration (yrs) 5.1  2.6 3.8  2.1 0.001†
Paroxysmal (% of patients) 67 70 0.64‡
Antiarrhythmic drugs (no. of trials) 2.9  2.2 2.2  1.4 0.007†
Medical history and conditions (% of patients)
No cardiovascular disease 36 37 0.88‡
Hypertension 44 44 0.99‡
Diabetes 10 11 0.81‡
CAD 22 24 0.73‡
Dilated cardiomyopathy 4 4 0.99
Valvular disease 8 9 0.79‡
Prior stroke or TIA 14 13 0.83‡
Cardiovascular drugs used 44 42 0.77‡
New York Heart Association functional class 1.4  0.8 1.3  0.6 0.31†
Hospital admission (times/yrs) 2.5  1.6 2.0  1.4 0.02†
*Plus-minus are means  SD. †P values by independent-samples t test. ‡By chi-squared test. By the Fisher exact test.
CAD  coronary artery disease, TIA  transient ischemic attack.
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encouragement for a prospective multicenter randomized
clinical trial to confirm our findings.
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